GLP-1 Receptor Agonists and Fertility: What You Need to Know

Weight-loss medications, specifically glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide and liraglutide, may influence fertility in women by promoting weight reduction and improving insulin sensitivity. While these medications effectively manage obesity and type 2 diabetes, clinical guidelines from the American College of Obstetricians and Gynecologists (ACOG) currently advise patients to discontinue these drugs at least two months before attempting conception due to insufficient data regarding their safety during pregnancy.

How Do GLP-1 Medications Affect Fertility?

GLP-1 receptor agonists primarily support fertility by addressing metabolic barriers to ovulation. According to the Endocrine Society, obesity is a significant contributor to ovulatory dysfunction, often linked to polycystic ovary syndrome (PCOS). By facilitating significant weight loss, these medications can help restore hormonal balance, decrease insulin resistance, and normalize the menstrual cycle in patients who previously experienced irregular ovulation.

However, the rapid improvement in metabolic health can lead to unexpected pregnancies. Clinical reports have documented instances where patients on GLP-1 therapy conceived despite using oral contraceptives. This is likely because the medications can delay gastric emptying, which may decrease the absorption of oral birth control pills, potentially rendering them less effective.

Why Is Discontinuation Required Before Pregnancy?

The primary concern for clinicians is the potential for fetal harm during early development. Because GLP-1 receptor agonists have a long half-life, the medication remains in the bloodstream for several weeks after the final dose. According to the U.S. Food and Drug Administration (FDA), animal studies have shown potential risks of developmental toxicity, including fetal structural abnormalities and pregnancy loss, when these drugs are administered during organogenesis.

While human clinical trials on pregnancy outcomes are ongoing, the current medical consensus is to prioritize a “washout” period. This allows the medication to be fully cleared from the system before a pregnancy begins, minimizing the risk of exposure during the most critical stages of fetal development.

Key Considerations for Patients

• The Two-Month Rule: Providers generally recommend stopping GLP-1 therapy at least eight weeks before trying to conceive.
• Contraceptive Efficacy: Patients should discuss alternative, non-oral forms of contraception (such as IUDs or implants) with their physician if they are taking GLP-1 medications and wish to prevent pregnancy.
• Preconception Counseling: Managing weight through medication is a medical intervention that requires close oversight by an endocrinologist or reproductive specialist when pregnancy is the goal.

Current Research vs. Clinical Practice

There is a distinct contrast between the metabolic benefits of GLP-1s and the current regulatory caution. Researchers are currently tracking pregnancy outcomes through registries, such as those maintained by Novo Nordisk, to gather real-world data on exposure. Until these data are peer-reviewed and confirm a safety profile, the clinical standard remains strict adherence to the manufacturer’s recommended washout periods. Patients should never discontinue or initiate these medications without consulting their primary care provider or OB-GYN to ensure that their metabolic health and fertility plans are safely aligned.